Matrix metalloproteinase inhibition therapy for vascular diseases

Vascular Pharmacology

Volumn 56, Issue 5-6, 2012, Pages 232-244

  Newby, Andrew C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Aneurysms; Atherosclerosis; Gene therapy; Metalloproteinase inhibitors; Restenosis

Indexed keywords

CELL SURFACE PROTEIN; DOXYCYCLINE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE INHIBITOR; TETRACYCLINE DERIVATIVE; ENZYME INHIBITOR;

ABDOMINAL AORTA ANEURYSM; APOPTOSIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROTIC PLAQUE; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM; ENDOTHELIUM CELL; ENZYME DEGRADATION; ENZYME INHIBITION; EROSION; EXTRACELLULAR MATRIX; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; REVIEW; RUPTURE; TISSUE REPAIR; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; ANIMAL; ATHEROSCLEROSIS; DISEASE MODEL; DRUG ANTAGONISM; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; VASCULAR DISEASES;

EID: 84863543450     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.01.007     Document Type: Review

References (214)

1. Abdul-Hussien, H., Soekhoe, R.G., Weber, E., von der Thusen, J.H., Kleemann, R., Mulder, A., van Bockel, J.H., Hanemaaijer, R., Lindeman, J.H., 2007. Collagen degradation in the abdominal aneurysm: a conspiracy of matrix metalloproteinase and cysteine collagenases. Am. J. Pathol. 170, 809-817.
2. Abdul-Hussien, H., Hanemaaijer, R., Verheijen, J.H., van Bockel, J.H., Geelkerken, R.H., Lindeman, J.H., 2009. Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J. Vasc. Surg. 49, 741-749.
3. Agrawal, A., Romero-Perez, D., Jacobsen, J.A., Villarreal, F.J., Cohen, S.M., 2008. Zincbinding groups modulate selective inhibition of MMPs. ChemMedChem 3, 812-820.
4. Aguilera, C.M., George, S.J., Johnson, J.L., Newby, A.C., 2003. Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein. Cardiovasc. Res. 58, 679-688.
5. Arbustini, E., Dal Bello, B., Morbini, P., Burke, A.P., Bocciarelli, M., Specchia, G., Virmani, R., 1999. Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. Heart 82, 269-272.
6. Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C.B., Seed, B., 1990. Cd44 is the principal cell-surface receptor for hyaluronate. Cell 61, 1303-1313.
7. Axisa, B., Loftus, I.M., Naylor, A.R., Goodall, S., Jones, L., Bell, P.R., Thompson, M.M., 2002. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 33, 2858-2864.
8. Baker, A.H., Zaltsman, A.B., George, S.J., Newby, A.C., 1998. Divergent effects of tissue inhibitors ofmetalloproteinase-1, -2 or -3 on rat vascular smoothmuscle cell invasion, proliferation and death in vitro: TIMP-3 promotes apoptosis. J. Clin. Invest. 101, 1478-1487.
9. Bar-Or, A., Nuttall, R.K., Duddy, M., Alter, A., Kim, H.J., Ifergan, I., Pennington, C.J., Bourgoin, P., Edwards, D.R., Yong, V.W., 2003. Analyses of allmatrixmetalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 126, 2738-2749.
10. Bartoli, M.A., Parodi, F.E., Chu, J., Pagano, M.B., Mao, D., Baxter, B.T., Buckley, C., Ennis, T.L., Thompson, R.W., 2006. Localized administration of doxycycline suppresses aortic dilatation in an experimental mouse model of abdominal aortic aneurysm. Ann. Vasc. Surg. 20, 228-236.
11. Baxter, B.T., Pearce, W.H., Waltke, E.A., Littooy, F.N., Hallett Jr., J.W., Kent, K.C., Upchurch Jr., G.R., Chaikof, E.L., Mills, J.L., Fleckten, B., Longo, G.M., Lee, J.K., Thompson, R.W., 2002. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J. Vasc. Surg. 36, 1-12.
12. Bendeck, M.P., Irvin, C., Reidy, M.A., 1996. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ. Res. 78, 38-43.
13. Bendeck, M.P., Conte,M., Zhang, M., Nili, N., Strauss, B.H., Farwell, S.M., 2002. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am. J. Pathol. 160, 1089-1095.
14. Berceli, S.A., Jiang, Z.H., Klingman, N.V., Schultz, G.S., Ozaki, C.K., 2006. Early differential MMP-2 and-9 dynamics during flow-induced arterial and vein graft adaptations. J. Surg. Res. 134, 327-334.
15. Bigatel, D.A., Elmore, J.R., Carey, D.J., Cizmeci-Smith, G., Franklin, D.P., Youkey, J.R., 1999. The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. J. Vasc. Surg. 29, 130-138 discussion 138-139.
16. Bond, M., Chase, A.J., Baker, A.H., Newby, A.C., 2001. Inhibition of transcription factor NF-κB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc. Res. 50, 556-565.
17. Boyle, J.R., McDermott, E., Crowther, M., Wills, A.D., Bell, P.R., Thompson, M.M., 1998. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease. J. Vasc. Surg. 27, 354-361.
18. Brooks, A.R., Lelkes, P.I., Rubanyi, G.M., 2002. Gene expression profiling of human aortic endothelial cells exposed to disturbed flow and steady laminar flow. Physiol. Genomics 9, 27-41.
19. Brown, D.L., Desai, K.K., Vakili, B.A., Nouneh, C., Lee, H.-M., Golub, L.M., 2004. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler. Thromb. Vasc. Biol. 24, 733-738.
20. Burbridge, M.F., Cogé, F., Galizzi, J.P., Boutin, J.A., West, D.C., Tucker, G.C., 2002. The role of the matrix metalloproteinases during in vitro vessel formation. Angiogenesis 5, 215-226.
21. Burke, A.P., Farb, A., Malcom, G.T., Liang, Y.H., Smialek, J., Virmani, R., 1997. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N. Engl. J. Med. 336, 1276-1282.
22. Burke, A.P., Farb, A., Malcom, G.T., Liang, Y., Smialek, J., Virmani, R., 1998. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 97, 2110-2116.
23. Carrell, T.W., Burnand, K.G., Wells, G.M., Clements, J.M., Smith, A., 2002. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 105, 477-482.
24. Castier, Y., Brandes, R.P., Leseche, G., Tedgui, A., Lehoux, S., 2005. P47phox-dependent NADPH oxidase regulates flow-induced vascular remodeling. Circ. Res. 97, 533-540.
25. Chase, A., Bond, M., Crook, M.F., Newby, A.C., 2002. Role of nuclear factor-κB activation in metalloproteinase-1, -3 and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler. Thromb. Vasc. Biol. 22, 765-771.
26. Chen, B.P.C., Li, Y.-S., Zhao, Y., Chen, K.-D., Li, S., Lao, J., Yuan, S., Shyy, J.Y.J., Chien, S.H.U., 2001. DNA microarray analysis of gene expression in endothelial cells in response to 24-h shear stress. Physiol. Genomics 7, 55-63.
27. Chen, X.F., Wang, J.A., Hou, J., Gui, C., Tang, L.J., Chen, X.Q., Xie, X.J., Jiang, J.J., Cai, J.F., Chen, H.S., Lu, H.S., Chen, H., 2009. Extracellular matrix metalloproteinase inducer (EMMPRIN) is present in smooth muscle cells of human aneurysmal aorta and is induced by angiotensin II in vitro. Clin. Sci. (Lond) 116, 819-826.
28. Cheng, L., Mantile, G., Pauly, R., Nater, C., Felici, A., Monticone, R., Bilato, C., Gluzband, Y.A., Crow, M.T., Stetler-Stevenson,W., Capogrossi, M.C., 1998. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation 98, 2195-2201.
29. Cherr, G.S., Motew, S.J., Travis, J.A., Fingerle, J., Fisher, L., Brandl, M., Williams, J.K., Geary, R.L., 2002. Metalloproteinase inhibition and the response to angioplasty and stenting in atherosclerotic primates. Arterioscler. Thromb. Vasc. Biol. 22, 161-166.
30. Cho, A., Reidy, M.A., 2002. Matrix metalloproteinase-9 is necessary for the regulation of smoothmuscle cell replication andmigration after arterial injury. Circ. Res. 91, 845-851.
31. Chung, A.W., Yang, H.H., Radomski, M.W., van Breemen, C., 2008. Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in marfan syndrome through the inhibition of matrix metalloproteinase-2 and -9. Circ. Res. 102, e73-e85.
32. Clark, J.C., Thomas, D.M., Choong, P.F., Dass, C.R., 2007. RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev. 26, 675-683.
33. Clark, I.M., Swingler, T.E., Sampieri, C.L., Edwards, D.R., 2008. The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol. 40, 1362-1378.
34. Clutterbuck, A.L., Asplin, K.E., Harris, P., Allaway, D., Mobasheri, A., 2009. Targeting matrix metalloproteinases in inflammatory conditions. Curr. drug targets 10, 1245-1254.
35. Crowther, M., Goodall, S., Jones, J.L., Bell, P.R., Thompson, M.M., 2000. Localization of matrix metalloproteinase 2 within the aneurysmal and normal aortic wall. Br. J. Surg. 87, 1391-1400.
36. Curci, J.A., Liao, S., Huffman, M.D., Shapiro, S.D., Thompson, R.W., 1998a. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J. Clin. Invest. 102, 1900-1910.
37. Curci, J.A., Petrinec, D., Liao, S., Golub, L.M., Thompson, R.W., 1998b. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J. Vasc. Surg. 28, 1082-1093.
38. Curci, J.A., Mao, D., Bohner, D.G., Allen, B.T., Rubin, B.G., Reilly, J.M., Sicard, G.A., Thompson, R.W., 2000. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J. Vasc. Surg. 31, 325-342.
39. Dai, G.H., Kaazempur-Mofrad, M.R., Natarajan, S., Zhang, Y.Z., Vaughn, S., Blackman, B.R., Kamm, R.D., Garcia-Cardena, G., Gimbrone, M.A., 2004. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosissusceptible and -resistant regions of human vasculature. Proc. Natl. Acad. Sci. U. S. A. 101, 14871-14876.
40. Davis, V., Persidskaia, R., Baca-Regen, L., Itoh, Y., Nagase, H., Persidsky, Y., Ghorpade, A., Baxter, B.T., 1998. Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 18, 1625-1633.
41. de Nooijer, R., Verkleij, C.J.N., von der Thusen, J.H., Jukema, J.W., van der Wall, E.E., van Berkel, T.J.C., Baker, A.H., Biessen, E.A.L., 2006. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler. Thromb. Vasc. Biol. 26, 340-346.
42. Deguchi, J.-O., Aikawa, E., Libby, P., Vachon, J.R., Inada, M., Krane, S.M., Whittaker, P., Aikawa, M., 2005. Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization inmouse atherosclerotic plaques. Circulation 112, 2708-2715.
43. Dekker, R.J., Boon, R.A., Rondaij, M.G., Kragt, A., Volger, O.L., Elderkamp, Y.W., Meijers, J.C.M., Voorberg, J., Pannekoek, H., Horrevoets, A.J.G., 2006. KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium. Blood 107, 4354-4363.
44. Deng, G.G., Martin-McNulty, B., Sukovich, D.A., Freay, A., Halks-Miller, M., Thinnes, T., Loskutoff, D.J., Carmeliet, P., Dole,W.P.,Wang, Y.X., 2003. Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ. Res. 92, 510-517.
45. Devel, L., Rogakos, V., David, A., Makaritis, A., Beau, F., Cuniasse, P., Yiotakis, A., Dive, V., 2006. Development of selective inhibitors and substrate of matrix metalloproteinase-12. J. Biol. Chem. 281, 11152-11160.
46. Devy, L., Dransfield, D.T., 2011. New strategies for the next generation of matrixmetalloproteinase inhibitors: selectively targeting membrane-anchored MMPs with therapeutic antibodies. Biochem. Res. Int. 2011.
47. Devy, L., Huang, L., Naa, L., Yanamandra, N., Pieters, H., Frans, N., Chang, E., Tao, Q., Vanhove, M., Lejeune, A., van Gool, R., Sexton, D.J., Kuang, G., Rank, D., Hogan, S., Pazmany, C., Ma, Y.L., Schoonbroodt, S., Nixon, A.E., Ladner, R.C., Hoet, R., Henderikx, P., Tenhoor, C., Rabbani, S.A., Valentino, M.L., Wood, C.R., Dransfield, D.T., 2009. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 69, 1517-1526.
48. Ding, R., McGuinness, C.L., Burnand, K.G., Sullivan, E., Smith, A., 2005. Matrix metalloproteinases in the aneurysm wall of patients treated with low-dose doxycycline. Vascular 13, 290-297.
49. Dodd, B.R., Spence, R.A., 2011. Doxycycline Inhibition of Abdominal Aortic Aneurysm Growth - A Systematic Review of the Literature. Current vascular pharmacology 9, 471-478.
50. Dollery, C.M., Humphries, S.E., McClelland, A., Latchman, D.S., McEwan, J.R., 1999. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 99, 3199-3205.
51. Dollery, C.M., Owen, C.A., Sukhova, G.K., Krettek, A., Shapiro, S.D., Libby, P., 2003. Neutrophil elastase in human atherosclerotic plaques. Production by macrophages. Circ. Res. 107, 2829-2836.
52. Dorman, G., Cseh, S., Hajdu, I., Barna, L., Konya, D., Kupai, K., Kovacs, L., Ferdinandy, P., 2010. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs 70, 949-964.
53. Duhamel-Clérin, E., Orvain, C., Lanza, F., Cazenave, J.-P., Klein-Soyer, C., 1997. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3 in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 17, 1931-1938.
54. Dumont, O., Loufrani, L., Henrion, D., 2007. Key role of the NO-pathway and matrix metalloprotease-9 in high blood flow-induced remodeling of rat resistance arteries. Arterioscler. Thromb. Vasc. Biol. 27, 317-324.
55. Dwivedi, A., Slater, S.C., George, S.J., 2009. MMP-9 and -12 cause N-cadherin shedding and thereby beta-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc. Res. 81, 178-186.
56. Engel, C.K., Pirard, B., Schimanski, S., Kirsch, R., Habermann, J., Klingler, O., Schlotte, V., Weithmann, K.U., Wendt, K.U., 2005. Structural basis for the highly selective inhibition of MMP-13. Chem. Biol. 12, 181-189.
57. Eriksson, E.E., 2011. Intravital microscopy on atherosclerosis in apolipoprotein Edeficient mice establishes microvessels as major entry pathways for leukocytes to advanced lesions/clinical perspective. Circulation 124, 2129-2138.
58. Filippov, S., Koenig, G.C., Chun, T.H., Hotary, K.B., Ota, I., Bugge, T.H., Roberts, J.D., Fay, W.P., Birkedal-Hansen, H., Holmbeck, K., Sabeh, F., Allen, E.D., Weiss, S.J., 2005. MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J. Exp. Med. 202, 663-671.
59. Folkesson, M., Kazi, M., Zhu, C., Silveira, A., Hemdahl, A.L., Hamsten, A., Hedin, U., Swedenborg, J., Eriksson, P., 2007. Presence of NGAL/MMP-9 complexes in human abdominal aortic aneurysms. Thromb. Haemost. 98, 427-433.
60. Forough, R., Koyama, M., Hasenstab, D., Lea, H., Clowes, M., Nikkari, S.T., Clowes, A.W., 1996. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ. Res. 79, 812-820.
61. Franco, C., Ho, B., Mulholland, D., Hou, G., Islam, M., Donaldson, K., Bendeck, M.P., 2006. Doxycycline alters vascular smooth muscle cell adhesion, migration, and reorganization of fibrillar collagen matrices. Am. J. Pathol. 168, 1697-1709.
62. Fukumoto, Y., Deguchi, J.-O., Libby, P., Rabkin-Aikawa, E., Sakata, Y., Chin, M.T., Hill, C.C., Lawler, P.R., Varo, N., Schoen, F.J., Krane, S.M., Aikawa, M., 2004. Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques. Circulation 110, 1953-1959.
63. Galis, Z.S., Johnson, C., Godin, D., Magid, R., Shipley, J.M., Senior, R.M., Ivan, E., 2002. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ. Res. 91, 852-859.
64. George, S.J., Angelini, G.D., Newby, A.C., Baker, A.H., 1998a. Adenovirus mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointima formation in human saphenous vein. Hum. Gene Ther. 9, 867-877.
65. George, S.J., Baker, A.H., Angelini, G.D., Newby, A.C., 1998b. Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther. 5, 1552-1560.
66. George, S.J., Lloyd, C.T., Angelini, G.D., Newby, A.C., Baker, A.H., 2000. Gene therapy for vein graft disease: tissue inhibitor of metalloproteinase-3 inhibits metalloproteinases, promotes apoptosis and reduces neointima formation in vitro and in vivo. Circulation 101, 296-304.
67. George, S.J., Wan, S., Hu, J., MacDonald, R., Johnson, J.L., Baker, A.H., 2011. Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation 124, S135-S142.
68. Gerdes, N., Sukhova, G.K., Libby, P., Reynolds, R.S., Young, J.L., Schonbeck, U., 2002. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J. Exp. Med. 195, 245-257.
69. Godin, D., Ivan, E., Johnson, C., Magid, R., Galis, Z.S., 2000. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation 102, 2861-2866.
70. Golledge, J., Norman, P.E., 2011. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis 217, 57-63.
71. Goodall, S., Crowther, M., Hemingway, D.M., Bell, P.R., Thompson, M.M., 2001. Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation 104, 304-309.
72. Gough, P.J., Gomez, I.G., Wille, P.T., Raines, E.W., 2006. Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J. Clin. Invest. 116, 59-69.
73. Grams, F., Brandstetter, H., D'Alo, S., Geppert, D., Krell, H.W., Leinert, H., Livi, V., Menta, E., Oliva, A., Zimmermann, G., Gram, F., Livi, V.E., 2001. Pyrimidine-2,4,6-Triones: a new effective and selective class of matrix metalloproteinase inhibitors. Biol. Chem. 382, 1277-1285.
74. Guenther, A., Gordon, S., Tiemann, M., Burger, R., Bakker, F., Green, J.R., Baum, W., Roelofs, A.J., Rogers, M.J., Gramatzki, M., 2010. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int. J. Cancer 126, 239-246.
75. Haas, T.L., Stitelman, D., Davis, S.J., Apte, S.S., Madri, J.A., 1999. Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J. Biol. Chem. 274, 22679-22685.
76. Hackmann, A.E., Rubin, B.G., Sanchez, L.A., Geraghty, P.A., Thompson, R.W., Curci, J.A., 2008. A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J. Vasc. Surg. 48, 519-526 discussion 526.
77. Hajduk, P.J., Shuker, S.B., Nettesheim, D.G., Craig, R., Augeri, D.J., Betebenner, D., Albert, D.H., Guo, Y., Meadows, R.P., Xu, L., Michaelides, M., Davidsen, S.K., Fesik, S.W., 2002. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability. J. Med. Chem. 45, 5628-5639.
78. Halpert, I., Sires, U.I., Roby, J.D., PotterPerigo, S., Wight, T.N., Shapiro, S.D., Welgus, H.G., Wickline, S.A., Parks, W.C., 1996. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc. Natl. Acad. Sci. U. S. A. 93, 9748-9753.
79. Han, X.Y., Boyd, P.J., Colgan, S., Madri, J.A., Haas, T.L., 2003. Transcriptional upregulation of endothelial cellmatrix metalloproteinase-2 in response to extracellular cues involves GATA-2. J. Biol. Chem. 278, 47785-47791.
80. Hattori, Y., Nerusu, K.C., Bhagavathula, N., Brennan, M., Hattori, N., Murphy, H.S., Su, L.D., Wang, T.S., Johnson, T.M., Varani, J., 2003. Vascular expression of matrix metalloproteinase-13 (collagenase-3) in basal cell carcinoma. Exp. Mol. Pathol. 74, 230-237.
81. Hemdahl, A.-L., Gabrielsen, A., Zhu, C., Eriksson, P., Hedin, U., Kastrup, J., Thoren, P., Hansson, G.K., 2006. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 26, 136-142.
82. Herman, M.P., Sukhova, G.K., Libby, P., Gerdes, N., Tang, N., Horton, D.B., Kilbride, M., Breitbart, R.E., Chun, M., Schonbeck, U., 2001. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 104, 1899-1904.
83. Holnthoner, W., Kerenyi, M., Groger, M., Kratochvill, F., Petzelbauer, P., 2006. Regulation of matrilysin expression in endothelium by fibroblast growth factor-2. Biochem. Biophys. Res. Commun. 342, 725-733.
84. Hong, H., Yang, Y., Liu, B., Cai, W., 2010. Imaging of abdominal aortic aneurysm: the present and the future. Curr. Vasc. Pharmacol. 8, 808-819.
85. Hu, J., Van den Steen, P.E., Sang, Q.X., Opdenakker, G., 2007. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6, 480-498.
86. Huang, Y., Song, L.X., Wu, S., Fan, F., Lopes-Virella, M.F., 2001. Oxidized LDL differentially regulatesMMP-1 and TIMP-1 expression in vascular endothelial cells. Atherosclerosis 156, 119-125.
87. Ikonomidis, J.S., Barbour, J.R., Amani, Z., Stroud, R.E., Herron, A.R., McClister Jr., D.M., Camens, S.E., Lindsey, M.L., Mukherjee, R., Spinale, F.G., 2005. Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation 112, I242-I248.
88. Islam, M.M., Franco, C.D., Courtman, D.W., Bendeck, M.P., 2003. A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening. Am. J. Pathol. 163, 1557-1566.
89. Itoh, Y., 2006. MT1-MMP: a key regulator of cell migration in tissue. IUBMB Life 58, 589-596.
90. Jackson, V., Olsson, T., Kurtovic, S., Folkersen, L., Paloschi, V., Wagsater, D., Franco-Cereceda, A., Eriksson, P., 2011. Matrix metalloproteinase 14 and 19 expression is associated with thoracic aortic aneurysms. J. Thorac. Cardiovasc. Surg.
91. Johnson, C., Galis, Z.S., 2004. Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler. Thromb. Vasc. Biol. 24, 54-60.
92. Johnson, J.L., Carson, K., Williams, H.M., Karanam, S., Newby, A.C., Angelini, G.D., George, S.J., Jackson, C.L., 2005a. Plaque rupture after short periods of fat-feeding in the apolipoprotein E knockout mouse: model characterisation, and effects of pravastatin treatment. Circulation 111, 1422-1430.
93. Johnson, J.L., George, S.J., Newby, A.C., Jackson, C.L., 2005b. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc. Natl. Acad. Sci. U. S. A. 102, 15575-15580.
94. Johnson, J.L., Baker, A.H., Oka, K., Chan, L., Newby, A.C., Jackson, C.L., George, S.J., 2006a. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: involvement of macrophage migration and apoptosis. Circulation 113, 2435-2444.
95. Johnson, J.L., Fritsche-Danielson, R., Behrendt, M., Westin-Eriksson, A., Wennbo, H., Herslof, M., Elebring, M., George, S.J., McPheat, W.L., Jackson, C.L., 2006b. Effect of broad-spectrum matrix metalloproteinase inhibition on atherosclerotic plaque stability. Cardiovasc. Res. 71, 586-595.
96. Johnson, J.L., Sala-Newby, G.B., Ismail, Y., Aguilera, C.M., Newby, A.C., 2008. Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler. Thromb. Vasc. Biol. 28, 1647-1653.
97. Johnson, J.L., Devel, L., Czarny, B., George, S.J., Jackson, C.L., Rogakos, V., Beau, F., Yiotakis, A., Newby, A.C., Dive, V., 2011a. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein Eknockout mice. Arterioscler. Thromb. Vasc. Biol. 31, 528-535.
98. Johnson, J.L., Dwivedi, A., Somerville, M., George, S.J., Newby, A.C., 2011b. Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler. Thromb. Vasc. Biol. 31, e35-e44.
99. Kadl, A.,Meher, A.K., Sharma, P.R., Lee,M.Y., Doran, A.C., Johnstone, S.R., Elliott, M.R.,Gruber, F., Han, J., Chen,W.,Kensler, T., Ravichandran,K.S., Isakson, B.E.,Wamhoff, B.R., Leitinger, N., 2010. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ. Res. 107, 737-746.
100. Kubo, T., Imanishi, T., Takarada, S., Kuroi, A., Ueno, S., Yamano, T., Tanimoto, T., Matsuo, Y., Masho, T., Kitabata, H., Tsuda, K., Tomobuchi, Y., Akasaka, T., 2007. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J. Am. Coll. Cardiol. 50, 933-939.
101. Kuzuya, M., Kanda, S., Sasaki, T., Tamaya-Mori, N., Cheng, X.W., Itoh, T., Itohara, S., Iguchi, A., 2003. Deficiency of gelatinase A suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 108, 1375-1381.
102. Kuzuya, M., Nakamura, K., Sasaki, T., Wu Cheng, X., Itohara, S., Iguchi, A., 2006. Effect of MMP-2 deficiency on atherosclerotic lesion formation in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 26, 1120-1125.
103. Lafleur, M.A., Hollenberg, M.D., Atkinson, S.J., Knauper, V., Murphy, G., Edwards, D.R., 2001. Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. Biochem. J. 357, 107-115.
104. Lagente, V., Boichot, E., 2010. Role of matrix metalloproteinases in the inflammatory process of respiratory diseases. J. Mol. Cell. Cardiol. 48, 440-444.
105. Laxton, R.C., Hu, Y., Duchene, J., Zhang, F., Zhang, Z., Leung, K.Y., Xiao, Q., Scotland, R.S., Hodgkinson, C.P., Smith, K., Willeit, J., Lopez-Otin, C., Simpson, I.A., Kiechl, S., Ahluwalia, A., Xu, Q., Ye, S., 2009. A role of matrix metalloproteinase-8 in atherosclerosis. Circ. Res. 105, 921-929.
106. Lemaitre, V., O'Byrne, T.K., Borczuk, A.C., Okada, Y., Tall, A.R., D'Armiento, J., 2001. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J. Clin. Invest. 107, 1227-1234.
107. Lemaitre, V., Soloway, P.D., D'Armiento, J., 2003. Increased medial degradation with pseudo-aneurysm formation in apolipoprotein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation 107, 333-338.
108. Li, A.H., Dubey, S., Varney, M.L., Dave, B.J., Singh, R.K., 2003. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol. 170, 3369-3376.
109. Li, Z., Clarke, M.P., Barker, M.D., McKie, N., 2005. TIMP3 mutation in Sorsby's fundus dystrophy: molecular insights. Expert Rev. Mol. Med. 7, 1-15.
110. Liang, J., Liu, E., Yu, Y., Kitajima, S., Koike, T., Jin, Y., Morimoto, M., Hatakeyama, K., Asada, Y., Watanabe, T., Sasaguri, Y., Watanabe, S., Fan, J., 2006. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation 113, 1993-2001.
111. Lindeman, J.H., Abdul-Hussien, H., van Bockel, J.H., Wolterbeek, R., Kleemann, R., 2009. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 119, 2209-2216.
112. Linder, S., 2007. The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. Trends Cell Biol. 17, 107-117.
113. Lindsay, M.E., Dietz, H.C., 2011. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature 473, 308-316.
114. Liu, J., Xiong, W., Baca-Regen, L., Nagase, H., Baxter, B.T., 2003. Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J. Vasc. Surg. 38, 1376-1383.
115. Lizarbe, T.R., Tarin, C., Gomez, M., Lavin, B., Aracil, E., Orte, L.M., Zaragoza, C., 2009. Nitric oxide induces the progression of abdominal aortic aneurysms through the matrix metalloproteinase inducer EMMPRIN. Am. J. Pathol. 175, 1421-1430.
116. Longo, G.M., Xiong, W., Greiner, T.C., Zhao, Y., Fiotti, N., Baxter, B.T., 2002. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 110, 625-632.
117. Longo, G.M., Buda, S.J., Fiotta, N., Xiong, W., Griener, T., Shapiro, S., Baxter, B.T., 2005. MMP-12 has a role in abdominal aortic aneurysms in mice. Surgery 137, 457-462.
118. Luan, Z., Chase, A.J., Newby, A.C., 2003. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol. 23, 769-775.
119. Luttun, A., Lutgens, E., Manderveld, A., Maris, K., Collen, D., Carmeliet, P., Moons, L., 2004. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 109, 1408-1414.
120. Mach, F., Schonbeck, U., Fabunmi, R.P., Murphy, C., Atkinson, E., Bonnefoy, J.Y., Graber, P., Libby, P., 1999. T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism - implications for tubule formation. Am. J. Pathol. 154, 229-238.
121. Mandriota, S.J., Seghezzi, G., Vassalli, J.D., Ferrara, N., Wasi, S., Mazzieri, R., Mignatti, P., Pepper, M.S., 1995. Vascular endothelial growth-factor increases urokinase receptor expression in vascular endothelial-cells. J. Biol. Chem. 270, 9709-9716.
122. Manicone, A.M., McGuire, J.K., 2008. Matrix metalloproteinases as modulators of inflammation. Semin. Cell Dev. Biol. 19, 34-41.
123. Manning, M.W., Cassis, L.A., Daugherty, A., 2003. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 23, 483-488.
124. Mao, D., Lee, J.K., VanVickle, S.J., Thompson, R.W., 1999. Expression of collagenase-3 (MMP-13) in human abdominal aortic aneurysms and vascular smooth muscle cells in culture. Biochem. Biophys. Res. Commun. 261, 904-910.
125. Marx, N., Froehlich, J., Siam, L., Ittner, J., Wierse, G., Schmidt, A., Scharnagl, H., Hombach, V., Koenig, W., 2003. Antidiabetic PPAR{gamma}-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 23, 283-288.
126. Monaco, C., Gregan, S.M., Navin, T.J., Foxwell, B.M., Davies, A.H., Feldmann, M., 2009. Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis. Circulation 120, 2462-2469.
127. Montero, I., Orbe, J., Varo, N., Beloqui, O., Monreal, J.I., Rodriguez, J.A., Diez, J., Libby, P., Paramo, J.A., 2006. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J. Am. Coll. Cardiol. 47, 1369-1378.
128. Moore, G., Liao, S., Curci, J.A., Starcher, B.C., Martin, R.L., Hendricks, R.T., Chen, J.J., Thompson, R.W., 1999. Suppression of experimental abdominal aortic aneurysms by systemic treatmentwith a hydroxamate-basedmatrixmetalloproteinase inhibitor (RS 132908). J. Vasc. Surg. 29, 522-532.
129. Mosorin, M., Juvonen, J., Biancari, F., Satta, J., Surcel, H.M., Leinonen, M., Saikku, P., Juvonen, T., 2001. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J. Vasc. Surg. 34, 606-610.
130. Musso, O., Theret, N., Campion, J.P., Turlin, B., Milani, S., Grappone, C., Clement, B., 1997. In situ detection of matrix metalloproteinase-2 (MMP2) and the metalloproteinase inhibitor TIMP2 transcripts in human primary hepatocellular carcinoma and in liver metastasis. J. Hepatol. 26, 593-605.
131. Nagase, H., Visse, R., Murphy, G., 2006. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69, 562-573.
132. Nagashima, Y., Hasegawa, S., Koshikawa, N., Taki, A., Ichikawa, Y., Kitamura, H., Misugi, K., Kihira, Y., Matuo, Y., Yasumitsu, H., Miyazaki, K., 1997. Expression of matrilysin in vascular endothelial cells adjacent to matrilysin-producing tumors. Int. J. Cancer 72, 441-445.
133. Nagel, S., Heinemann, P.V., Heiland, S., Koziol, J., Gardner, H., Wagner, S., 2010. Selective MMP-inhibition with Ro 28-2653 in acute experimental stroke-a magnetic resonance imaging efficacy study. Brain Res. 1368, 264-270.
134. Newby, A.C., 2005. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev. 85, 1-31.
135. Newby, A.C., 2006. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc. Res. 69, 614-624.
136. Newby, A.C., 2008. Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler. Thromb. Vasc. Biol. 28, 2108-2114.
137. Nollendorfs, A., Greiner, T.C., Nagase, H., Baxter, B.T., 2001. The expression and localization of membrane type-1 matrix metalloproteinase in human abdominal aortic aneurysms. J. Vasc. Surg. 34, 316-322.
138. Nordon, I.M., Hinchliffe, R.J., Loftus, I.M., Thompson, M.M., 2011. Pathophysiology and epidemiology of abdominal aortic aneurysms. Nat. Rev. Cardiol. 8, 92-102.
139. Oh, J., Takahashi, R., Kondo, S., Mizoguchi, A., Adachi, E., Sasahara, R.M., Nishimura, S., Imamura, Y., Kitayama, H., Alexander, D.B., Ide, C., Horan, T.P., Arakawa, T., Yoshida, H., Nishikawa, S.I., Itoh, Y., Seiki, M., Itohara, S., Takahashi, C., Noda, M., 2001. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107, 789-800.
140. Oh, J., Seo, D.W., Diaz, T., Wei, B.Y., Ward, Y., Ray, J.M., Morioka, Y., Shi, S.L., Kitayama, H., Takahashi, C., Noda, M., Stetler-Stevenson, W.G., 2004. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cellmigration through increased expression of RECK. Cancer Res. 64, 9062-9069.
141. Page-McCaw, A., Ewald, A.J.,Werb, Z., 2007. Matrixmetalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8, 221-233.
142. Papalambros, E., Sigala, F., Georgopoulos, S., Menekakos, C., Giatromanolaki, A., Bastounis, E., Sivridis, E., 2003. Immunohistochemical expression of metalloproteinases MMP-2 and MMP-9 in abdominal aortic aneurysms: correlation with symptoms and aortic diameter. Int. J. Mol. Med. 12, 965-968.
143. Parks, W.C., Wilson, C.L., Lopez-Boado, Y.S., 2004. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4, 617-629.
144. Participants, T.U.S.A.T., 1998. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet 352, 1649-1655.
145. Partridge, C.R., Hawker, J.R., Forough, R., 2000. Overexpression of a secretory form of FGF-1 promotes MMP-1-mediated endothelial cell migration. J. Cell. Biochem. 78, 487-499.
146. Paulson, K.E., Zhu, S.N., Chen, M., Nurmohamed, S., Jongstra-Bilen, J., Cybulsky, M.I., 2010. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ. Res. 106, 383-390.
147. Peracchia, F., Tamburro, A., Prontera, C., Mariani, B., Rotilio, D., 1997. CAMP involvement in the expression of MMP-2 and MT-MMP1 metalloproteinases in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 17, 3185-3190.
148. Petersen, E., Gineitis, A., Wagberg, F., Angquist, K.A., 2000. Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture. Eur. J. Vasc. Endovasc. Surg. 20, 457-461.
149. Peterson, J.T., 2006. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 69, 677-687.
150. Petrinec, D., Liao, S., Holmes, D.R., Reilly, J.M., Parks, W.C., Thompson, R.W., 1996. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J. Vasc. Surg. 23, 336-346.
151. Plaisier, M., Kapiteijn, K., Koolwijk, P., Fijten, C., Hanemaaijer, R., Grimbergen, J.M., Mulder-Stapel, A., Quax, P.H., Helmerhorst, F.M., van Hinsbergh, V.W., 2004. Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: role of MT3-MMP. J. Clin. Endocrinol. Metab. 89, 5828-5836.
152. Polette, M., Clavel, C., Birembaut, P., Declerck, Y.A., 1993. Localization by in-situ hybridization of messenger-Rnas encoding stromelysin-3 and tissue inhibitors of metallo-proteinases Timp-1 and Timp-2 in human head and neck carcinomas. Pathol. Res. Pract. 189, 1052-1057.
153. Prall, A.K., Longo, G.M., Mayhan, W.G., Waltke, E.A., Fleckten, B., Thompson, R.W., Baxter, B.T., 2002. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J. Vasc. Surg. 35, 923-929.
154. Prescott, M.F., Sawyer,W.K., Von Linden-Reed, J., Jeune,M., Chou,M., Caplan, S.L., Jeng, A.Y., 1999. Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Ann. N. Y. Acad. Sci. 878, 179-190.
155. Puyraimond, A., Fridman, R., Lemesle,M., Arbeille, B., Menashi, S., 2001.MMP-2 colocalizes with caveolae on the surface of endothelial cells. Exp. Cell Res. 262, 28-36.
156. Pyo, R., Lee, J.K., Shipley, J.M., Curci, J.A., Mao, D., Ziporin, S.J., Ennis, T.L., Shapiro, S.D., Senior, R.M., Thompson, R.W., 2000. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Invest. 105, 1641-1649.
157. Qi, J.H., Ebrahem, Q., Moore, N., Murphy, G., Claesson-Welsh, L., Bond, M., Baker, A., Anand-Apte, B., 2003. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. 9, 407-415.
158. Quillard, T., Tesmenitsky, Y., Croce, K., Travers, R., Shvartz, E., Koskinas, K.C., Sukhova, G.K., Aikawa, E., Aikawa, M., Libby, P., 2011. Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 31, 2464-2472.
159. Rajavashisth, T.B., Liao, J.K., Galis, Z.S., Tripathi, S., Laufs, U., Tripathi, J., Chai, N.N., Xu, X.P., Jovinge, S., Shah, P.K., Libby, P., 1999. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J. Biol. Chem. 274, 11924-11929.
160. Reel, B., Oktay, G., Ozkal, S., Islekel, H., Ozer, E., Ozsarlak-Sozer, G., Cavdar, Z., Akhisaroglu, S.T., Kerry, Z., 2009. MMP-2 and MMP-9 alteration in response to collaring in rabbits: the effects of endothelin receptor antagonism. J. Cardiovasc. Pharmacol. Ther. 14, 292-301.
161. Reel, B., Sala-Newby, G.B., Huang, W.-C., Newby, A.C., 2011. Diverse patterns of cyclooxygenase-independent metalloproteinase gene regulation in human monocytes. Br. J. Pharmacol. 163, 1679-1690.
162. Reeps, C., Essler, M., Pelisek, J., Seidl, S., Eckstein, H.H., Krause, B.J., 2008. Increased 18Ffluorodeoxyglucose uptake in abdominal aortic aneurysms in positron emission/ computed tomography is associated with inflammation, aortic wall instability, and acute symptoms. J. Vasc. Surg. 48, 417-423 discussion 424.
163. Rouis, M., Adamy, C., Duverger, N., Lesnik, P., Horellou, P., Moreau, M., Emmanuel, F., Caillard, J.M., Laplaud, P.M., Dachet, C., Chapman, M.J., 1999. Adenovirus-mediate overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E deficient mice. Circulation 100, 533-540.
164. Rubino, M.T., Agamennone, M., Campestre, C., Campiglia, P., Cremasco, V., Faccio, R., Laghezza, A., Loiodice, F., Maggi, D., Panza, E., Rossello, A., Tortorella, P., 2011. Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption. ChemMedChem 6, 1258-1268.
165. Saito, S., Zempo, N., Yamashita, A., Takenaka, H., Fujioka, K., Esato, K., 2002. Matrix metalloproteinase expressions in arteriosclerotic aneurysmal disease. Vasc. Endovascular Surg. 36, 1-7.
166. Sakalihasan, N., Delvenne, P., Nusgens, B.V., Limet, R., Lapiere, C.M., 1996. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J. Vasc. Surg. 24, 127-133.
167. Sapadin, A.N., Fleischmajer, R., 2006. Tetracyclines: nonantibiotic properties and their clinical implications. J. Am. Acad. Dermatol. 54, 258-265.
168. Schleef, R.R., Bevilacqua, M.P., Sawdey, M., Gimbrone, M.A., Loskutoff, D.J., 1988. Cytokine activation of vascular endothelium - effects on tissue-type plasminogen-activator and type-1 plasminogen-activator inhibitor. J. Biol. Chem. 263, 5797-5803.
169. Schneider, F., Sukhova, G.K., Aikawa, M., Canner, J., Gerdes, N., Tang, S.M., Shi, G.P., Apte, S.S., Libby, P., 2008. Matrix-metalloproteinase-14 deficiency in bone-marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques. Circulation 117, 931-939.
170. Sheth, R.A., Maricevich, M., Mahmood, U., 2010. In vivo optical molecular imaging of matrix metalloproteinase activity in abdominal aortic aneurysms correlates with treatment effects on growth rate. Atherosclerosis 212, 181-187.
171. Shimizu, K., Shichiri, M., Libby, P., Lee, R.T., Mitchell, R.N., 2004. Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J. Clin. Invest. 114, 300-308.
172. Sho, E., Chu, J., Sho, M., Fernandes, B., Judd, D., Ganesan, P., Kimura, H., Dalman, R.L., 2004. Continuous periaortic infusion improves doxycycline efficacy in experimental aortic aneurysms. J. Vasc. Surg. 39, 1312-1321.
173. Silence, J., Lupu, F., Collen, D., Lijnen, H.R., 2001. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler. Thromb. Vasc. Biol. 21, 1440-1445.
174. Silence, J., Collen, D., Lijnen, H.R., 2002. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene. Circ. Res. 90, 897-903.
175. Sluijter, J.P., Pulskens, W.P., Schoneveld, A.H., Velema, E., Strijder, C.F., Moll, F., de Vries, J.P., Verheijen, J., Hanemaaijer, R., de Kleijn, D.P., Pasterkamp, G., 2006. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 37, 235-239.
176. Sood, R.R., Taheri, S., Candelario-Jalil, E., Estrada, E.Y., Rosenberg, G.A., 2008. Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J. Cereb. Blood Flow Metab. 28, 431-438.
177. Southgate, K.M., Mehta, D., Izzat, M.B., Newby, A.C., Angelini, G.D., 1999. Increased secretion of basement membrane degradingmetalloproteinases in pig saphenous vein into carotid artery interposition grafts. Arterioscler. Thromb. Vasc. Biol. 19, 1640-1649.
178. Stetler-Stevenson, W.G., 2008. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci. Signal. 1, re6.
179. Sukhova, G.K., Schonbeck, U., Rabkin, E., Schoen, F.J., Poole, A.R., Billinghurst, R.C., Libby, P., 1999. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 99, 2503-2509.
180. Takahashi, K., Ikura, M., Habashita, H., Nishizaki, M., Sugiura, T., Yamamoto, S., Nakatani, S., Ogawa, K., Ohno, H., Nakai, H., Toda, M., 2005. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach. Bioorg. Med. Chem. 13, 4527-4543.
181. Tedesco, M.M., Terashima, M., Blankenberg, F.G., Levashova, Z., Spin, J.M., Backer, M.V., Backer, J.M., Sho, M., Sho, E., McConnell, M.V., Dalman, R.L., 2009. Analysis of in situ and ex vivo vascular endothelial growth factor receptor expression during experimental aortic aneurysm progression. Arterioscler. Thromb. Vasc. Biol. 29, 1452-1457.
182. Tedgui, A., Mallat, Z., 2006. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86, 515-581.
183. Thomas, A.C., Sala-Newby, G.B., Ismail, Y., Johnson, J.L., Pasterkamp, G., Newby, A.C., 2007. Genomics of foam cells and nonfoamy macrophages from rabbits identifies arginase-I as a differential regulator of nitric oxide production. Arterioscler. Thromb. Vasc. Biol. 27, 571-577.
184. Thompson, R.W., Baxter, B.T., 1999. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann. N. Y. Acad. Sci. 878, 159-178.
185. Thompson, M., Cockerill, G., 2006. Matrix metalloproteinase-2: the forgotten enzyme in aneurysm pathogenesis. Ann. N. Y. Acad. Sci. 1085, 170-174.
186. Thompson, R.W., Holmes, D.R., Mertens, R.A., Liao, S., Botney, M.D., Mecham, R.P., Welgus, H.G., Parks, W.C., 1995. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J. Clin. Invest. 96, 318-326.
187. Treharne, G.D., Boyle, J.R., Goodall, S., Loftus, I.M., Bell, P.R., Thompson, M.M., 1999. Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Br. J. Surg. 86, 1053-1058.
188. Tromp, G., Gatalica, Z., Skunca, M., Berguer, R., Siegel, T., Kline, R.A., Kuivaniemi, H., 2004. Elevated expression of matrix metalloproteinase-13 in abdominal aortic aneurysms. Ann. Vasc. Surg. 18, 414-420.
189. Turner, G.H., Olzinski, A.R., Bernard, R.E., Aravindhan, K., Karr, H.W., Mirabile, R.C., Willette, R.N., Gough, P.J., Jucker, B.M., 2008. In vivo serial assessment of aortic aneurysm formation in apolipoprotein E-deficient mice via MRI. Circ. Cardiovasc. Imaging 1, 220-226.
190. van Hinsbergh, V.W., Koolwijk, P., 2008. Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead. Cardiovasc. Res. 78, 203-212.
191. Viemann, D., Goebeler, M., Schmid, S., Nordhues, U., Klimmek, K., Sorg, C., Roth, J., 2006. TNF induces distinct gene expression programs in microvascular and macrovascular human endothelial cells. J. Leukoc. Biol. 80, 174-185.
192. Vinh, A., Gaspari, T.A., Liu, H.B., Dousha, L.F., Widdop, R.E., Dear, A.E., 2008. A novel histone deacetylase inhibitor reduces abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. J. Vasc. Res. 45, 143-152.
193. Virmani, R., Kolodgie, F.D., Burke, A.P., Farb, A., Schwartz, S.M., 2000. Lessons from sudden coronary death - a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 20, 1262-1275.
194. Virmani, R., Burke, A.P., Farb, A., Kolodgie, F.D., 2006. Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 47, C13-C18.
195. Visse, R., Nagase, H., 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure function and biochemistry. Circ. Res. 92, 827-839.
196. Wang, H., Keiser, J.A., 2000. Hepatocyte growth factor enhances MMP activity in human endothelial cells. Biochem. Biophys. Res. Commun. 272, 900-905.
197. Wang, B.-W., Chang, H., Lin, S., Kuan, P., Shyu, K.-G., 2003. Induction of matrix metalloproteinases-14 and -2 by cyclical mechanical stretch is mediated by tumor necrosis factor-{alpha} in cultured human umbilical vein endothelial cells. Cardiovasc. Res. 59, 460-469.
198. Wang, J., Taba, Y., Pang, J., Yin, G., Yan, C., Berk, B.C., 2009. GIT1 mediates VEGF-induced podosome formation in endothelial cells: critical role for PLC{gamma}. Arterioscler. Thromb. Vasc. Biol. 29, 202-208.
199. Wang, Y., Ait-Oufella, H., Herbin, O., Bonnin, P., Ramkhelawon, B., Taleb, S., Huang, J., Offenstadt, G., Combadiere, C., Renia, L., Johnson, J.L., Tharaux, P.L., Tedgui, A., Mallat, Z., 2010. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J. Clin. Invest. 120, 422-432.
200. Wesselman, J.P.M., Kuijs, R., Hermans, J.J.R., Janssen, G.M.J., Fazzi, G.E., van Essen, H., Evelo, C.T.A., Struijker-Boudier, H.A.J., De Mey, J.G.R., 2004. Role of the Rhoa/Rho kinase system in flow-related remodeling of rat mesenteric small arteries in vivo. J. Vasc. Res. 41, 277-290.
201. Whalen, A.M., Chen, X.L., Qiu, F.H., Cook, C.K., Sinibaldi, D., Thomas, S., Varner, S.E., Rao, A.S., Wasserman, M.A., Medford, R.M., 2003. Global gene expression analysis of flow-conditioned endothelial cells: oscillatory flow induces a unique set of proinflammatory genes. FASEB J. 17, A274-A274.
202. White, S.J., Hayes, E., Newby, A.C., Unpublished data.
203. Williams, H., Johnson, J.L., Jackson, C.L., White, S.J., George, S.J., 2010. MMP-7 mediates cleavage of N-cadherin and promotes smooth muscle cell apoptosis. Cardiovasc. Res. 87, 137-146.
204. Wilson, W.R., Schwalbe, E.C., Jones, J.L., Bell, P.R., Thompson, M.M., 2005. Matrix metalloproteinase 8 (neutrophil collagenase) in the pathogenesis of abdominal aortic aneurysm. Br. J. Surg. 92, 828-833.
205. Wilson, W.R., Anderton, M., Schwalbe, E.C., Jones, J.L., Furness, P.N., Bell, P.R., Thompson, M.M., 2006. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. Circulation 113, 438-445.
206. Xiong, W., Knispel, R., Mactaggart, J., Baxter, B.T., 2006. Effects of tissue inhibitor of metalloproteinase 2 deficiency on aneurysm formation. J. Vasc. Surg. 44, 1061-1066.
207. Xiong, W., Knispel, R.A., Dietz, H.C., Ramirez, F., Baxter, B.T., 2008. Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome. J. Vasc. Surg. 47, 166-172 discussion 172.
208. Xiong, W., Knispel, R., MacTaggart, J., Greiner, T.C., Weiss, S.J., Baxter, B.T., 2009. Membrane-type 1 matrix metalloproteinase regulates macrophage-dependent elastolytic activity and aneurysm formation in vivo. J. Biol. Chem. 284, 1765-1771.
209. Yamashita, A., Noma, T., Nakazawa, A., Saito, S., Fujioka, K., Zempo, N., Esato, K., 2001. Enhanced expression of matrix metalloproteinase-9 in abdominal aortic aneurysms. World J. Surg. 25, 259-265.
210. Yana, I., Sagara, H., Takaki, S., Takatsu, K., Nakamura, K., Nakao, K., Katsuki, M., Taniguchi, S.-i., Aoki, T., Sato, H., Weiss, S.J., Seiki, M., 2007. Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J. Cell Sci. 120, 1607-1614.
211. Yang, H.H., Kim, J.M., Chum, E., van Breemen, C., Chung, A.W., 2010. Effectiveness of combination of losartan potassium and doxycycline versus single-drug treatments in the secondary prevention of thoracic aortic aneurysm in Marfan syndrome. J. Thorac. Cardiovasc. Surg. 140 (305-312), e302.
212. Yoshimura, K., Aoki, H., Ikeda, Y., Fujii, K., Akiyama, N., Furutani, A., Hoshii, Y., Tanaka, N., Ricci, R., Ishihara, T., Esato, K., Hamano, K., Matsuzaki, M., 2005. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat. Med. 11, 1330-1338.
213. Yun, S., Dardik, A., Haga, M., Yamashita, A., Yamaguchi, S., Koh, Y., Madri, J.A., Sumpio, B.E., 2002. Transcription factor Sp1 phosphorylation induced by shear stress inhibits membrane type 1-matrix metalloproteinase expression in endothelium. J. Biol. Chem. 277, 34808-34814.
214. Zempo, N., Koyama, N., Kenagy, R.D., Lea, H.J., Clowes, A.W., 1996. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler. Thromb. Vasc. Biol. 16, 28-33.